CMS final LCD denies coverage for Interpace's PancraGEN test; company to discontinue after Feb 7, 2025

INTERPACE BIOSCIENCES, INC.

CMS issued final LCD L39365 establishing non-coverage for PancraGEN, a DNA-based test assessing pancreatic cyst cancer risk.
Interpace will stop accepting PancraGEN specimens after February 7, 2025; test primarily ordered for Medicare patients.
PancraGEN has helped over 80,000 patients since 2013; CEO calls decision inconsistent with advancing patient care.
Company plans restructuring but expects to remain profitable with ThyGeNEXT + ThyraMIR v2 thyroid tests.
Interpace will consider all remedies against CMS/Novitas regarding the non-coverage decision.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.